IP Library Granted Patent US 10,517,898
Granted Patent B2
US 10,517,898 · App. 15/528,355 · Granted Dec 31, 2019

Compositions and methods related to hematologic recovery

Inventor: John P. Chute (Sherman Oaks, CA)
Assignee: The Regents of the University of California
A61K35/28A61K35/51C12N5/0647C12N5/0663C12N5/0665A61K2035/124C12N2501/73
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,517,898
App. No.
15/528,355
Granted
Dec 31, 2019
Kind
B2
Abstract

In some aspects, the invention relates to populations of hematopoietic cells that are enriched in PTPσ − cells and methods of use thereof.

Claims (17)

1. A method for implanting hematopoietic cells into a subject in need thereof, the method comprising:

obtaining a sample comprising hematopoietic cells;

contacting the sample with an inhibitor of the PTPσ pathway; and

transplanting the sample into the subject.

2. The method of claim 1 , wherein the inhibitor of the PTPσ pathway is a p250GAP antagonist.

3. The method of claim 1 , wherein the inhibitor of the PTPσ pathway is a Rac1 agonist.

4. The method of claim 1 , wherein the inhibitor of the PTPσ pathway is a small molecule or an interfering nucleic acid.

5. The method of claim 1 , wherein the method comprises removing PTPσ + , CD34 − , CD38 + , CD45RA + , CD90 − , lin + , Rho hi , CD49f − , and/or CD33 + cells from the sample.

6. The method of claim 1 , wherein the method comprises enriching the sample in PTPσ − , CD34 + , CD38 − , CD45RA − , CD90 + , lin − , Rho lo , CD49f +− , and/or CD33 − cells.

7. The method of any one of claim 1 , wherein the inhibitor of the PTPσ pathway is an interfering nucleic acid.

8. The method of claim 7 , wherein the inhibitor of the PTPσ pathway is an shRNA.

9. A method for promoting hematopoietic reconstitution in a subject in need thereof, the method comprising administering to the subject an inhibitor of a PTPσ pathway, wherein the subject has received an implant comprising hematopoietic cells, or wherein the method further comprises administering hematopoietic cells to the patient before the subject receives the PTPσ pathway inhibitor, simultaneously with the PTPσ pathway inhibitor, or after the subject receives the PTPσ pathway inhibitor.

10. The method of claim 9 , wherein the subject has compromised hematopoietic function.

11. The method of claim 9 , wherein the inhibitor of the PTPσ pathway is a PTPσ inhibitor.

12. The method of claim 9 , wherein the inhibitor of the PTPσ pathway is a p250GAP antagonist.

13. The method of claim 9 , wherein the inhibitor of the PTPσ pathway is a Rac1 agonist.

14. The method of claim 9 , wherein the inhibitor of the PTPσ pathway is a small molecule or an interfering nucleic acid.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 12, 2019
From: CHUTE, JOHN P.
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 050359/0841 →
CONFIRMATORY LICENSE Recorded Aug 29, 2017
From: UNIVERSITY OF CALIFORNIA LOS ANGELES
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 043702/0967 →
Continuity (2)
Provisional Application 62082425 · Nov 20, 2014
Related Publication 20170319624A1 · Nov 9, 2017